Insmed

Insmed is a prominent biopharmaceutical company founded in 1988, dedicated to developing and commercializing innovative therapies for patients suffering from serious and rare diseases. Operating within the global healthcare sector, the firm focuses on high-need therapeutic areas, including respiratory and neutrophil-mediated conditions. Insmed maintains a robust pipeline of novel drug candidates, leveraging advanced inhalation technologies to address complex medical challenges across the United States, Europe, and Japan.

The company currently employs 1,000-5,000 employees and manages operations across 10 locations worldwide. Its primary product portfolio includes ARIKAYCE, a critical treatment for Mycobacterium avium complex lung disease, alongside promising candidates like Brensocatib and Treprostinil Palmitil Inhalation Powder. Learn about Insmed's global headquarters for detailed information regarding their operational footprint in Bridgewater, New Jersey. The firm’s commitment to scientific discovery is supported by a large team of researchers and specialized operations staff, ensuring consistent delivery of life-changing therapies to patients globally.

With a fiscal year-end revenue of $819.6M, Insmed demonstrates significant market presence as a publicly traded entity on the NASDAQ under the ticker INSM. The company competes with major industry players such as United Therapeutics and Neurocrine Biosciences. Explore financial highlights to review their recent funding activities and revenue growth metrics. Meet Insmed's team to gain insights into the leadership and scientific expertise driving their strategic initiatives. Through continuous investment in R&D and strategic commercialization, Insmed remains a key player in the biopharmaceutical landscape, consistently advancing its mission to improve patient outcomes through precision medicine and innovative drug development.